Disc Medicine reports FY2025 net loss $212.2M; receives CRL for bitopertin; cash runway into 2029

Disc Medicine, Inc.

2025-FY EPS reported -$6.01

Net loss of $212.2M for FY2025, up from $109.4M in FY2024; driven by higher R&D and SG&A costs.
Cash, cash equivalents and marketable securities of $791.2M as of Dec 31, 2025, up from $489.9M.
FDA issued Complete Response Letter for bitopertin in EPP in Feb 2026; Phase 3 APOLLO topline data expected Q4 2026.
Phase 2 data for DISC-0974 in MF anemia showed durable hemoglobin benefits across subgroups at ASH.
DISC-3405 Phase 2 in PV and Phase 1b in SCD ongoing; initial data expected 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.